Evidence map›Paper›PMID 40539231›Full record

ReviewBioEssays : news and reviews in molecular, cellular and developmental biology2025

Physics of Protein Aggregation in Normal and Accelerated Brain Aging.

Alberto J Espay, Andrea Sturchio, Alberto Imarisio, Emily J Hill, Brady Williamson, Kora Montemagno, Christian Hoffmann, Hugo Le Roy, Dragomir Milovanovic, Fredric P Manfredsson

Abstract readReview
In one paragraph

Review in BioEssays : news and reviews in molecular, cellular and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alberto J EspayJames J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0002-3389-136X
Andrea SturchioSection of Neurology, Karolinska Institutet, Stockholm, Sweden.
Alberto ImarisioDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.ORCID https://orcid.org/0000-0002-1206-4170
Emily J HillJames J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
Brady WilliamsonDepartment of Radiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Kora MontemagnoCenter for functionally integrative neuroscience, Institute for Clinical Medicine, Aarhus University, Aarhus, Denmark.
Christian HoffmannLaboratory of Molecular Neuroscience, German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Hugo Le RoyInstitute of Physics, School of Basic Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Dragomir MilovanovicLaboratory of Molecular Neuroscience, German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Fredric P ManfredssonDepartment of Translational Neuroscience and the Muhammad Ali Parkinson Center, Barrow Neurological Institute, Phoenix, Arizona, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein aggregation is a normal response to age-related exposures. According to the thermodynamic hypothesis of protein folding, soluble proteins precipitate into amyloids (pathology) under supersaturated conditions through a process similar to crystallization. This soluble-to-insoluble phase transition occurs via nucleation and may be catalyzed by ectopic surfaces such as lipid nanoparticles, microbes, or chemical pollutants. The increasing prevalence of these exposures with age correlates with the rising incidence of pathology over the lifespan. However, the formation of amyloid fibrils does not inherently cause neurodegeneration. Neurodegeneration emerges when the levels of functional monomeric proteins, from which amyloids form, fall below a critical threshold. The preservation of monomeric proteins may explain neurological resilience, regardless of the extent of amyloid deposition. This biophysical framework challenges the traditional clinicopathological view that considers amyloids intrinsically toxic, despite the absence of a known mechanism of toxicity. Instead, it suggests that chronic exposures driving persistent nucleation consume monomeric proteins as they aggregate. In normal aging, replacement matches loss; in accelerated aging, it does not. A biophysical approach to neurodegenerative diseases has important therapeutic implications, refocusing treatment strategies from removing pathology to restoring monomeric protein homeostasis above the threshold needed to sustain normal brain function.

Indexed as

AgingBrainProtein AggregatesProtein Aggregation, PathologicalAmyloidAnimalsHumansNeurodegenerative DiseasesProtein FoldingThermodynamicsAmyloidProtein AggregatesAlzheimer's diseaseamyloidcross‐betanucleationParkinson's diseaseseed amplification assaysupersaturation

Identifiers

PMID40539231
PMCPMC12278810

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.